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Preclinical studies suggest that fasting prior to chemotherapy may be an effective strat-
egy to protect patients against the adverse effects of chemo-toxicity. Fasting may also 
sensitize cancer cells to chemotherapy. It is further suggested that fasting may similarly 
augment the efficacy of oncolytic viral therapy. The primary mechanism mediating these 
beneficial effects is thought to relate to the fact that fasting results in a decrease of 
circulating growth factors. In turn, such fasting cues would prompt normal cells to 
redirect energy toward cell maintenance and repair processes, rather than growth and 
proliferation. However, fasting is also known to upregulate autophagy, an evolutionarily 
conserved catabolic process that is upregulated in response to various cell stressors. 
Here, we review a number of mechanisms by which fasting-induced autophagy may 
have an impact on both chemo-tolerance and chemo-sensitization. First, fasting may 
exert a protective effect by mobilizing autophagic components prior to chemo-in-
duction. In turn, the autophagic apparatus can be repurposed for removing cellular 
components damaged by chemotherapy. Autophagy also plays a key role in epitope 
expression as well as in modulating inflammation. Chemo-sensitization resulting from 
fasting may in fact be an effect of enhanced immune surveillance as a result of better 
autophagy-dependent epitope processing. Finally, autophagy is involved in host defense 
against viruses, and aspects of the autophagic process are also often targets for viral 
subversion. Consequently, altering autophagic flux by fasting may alter viral infectivity. 
These observations suggest that fasting-induced autophagy may have an impact on 
therapeutic efficacy in various oncological contexts.
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inTRODUCTiOn
A major hurdle in the fight against cancer is the narrow therapeutic window associated with 
cytotoxic chemotherapeutic agents. Strategies aimed at decreasing the toxic effect associated with 
chemotherapeutic interventions face the risk of similarly protecting cancer cells, thus abrogating 
the therapeutic effect of antineoplastic therapies. In this regard, short-term fasting has emerged 
as a potential intervention that may alleviate various side-effects associated with chemotherapy, 
without attenuating the antineoplastic efficacy of the chemotherapeutic agent. Initial studies have 
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demonstrated that mice fasted for 48–60 h were protected against 
a lethal dose of etoposide, a chemotherapeutic with a notoriously 
narrow therapeutic window (1). This result was observed in three 
different mice strains and did not attenuate the therapeutic effi-
cacy of etoposide against cancer cells (1). In a subsequent study 
(2), fasting conditions were shown to sensitize various cancers to 
a range of chemotherapeutics and even attenuate the growth of 
certain cancers in vitro. A clinical trial testing the feasibility of 
incorporating short-term fasting (72-h fasting around the time 
when the therapeutic agent is administered) into platinum-based 
chemotherapy (3) found fasting to be well tolerated. Moreover, 
results also indicated that fasting did not protect cancer cells. 
Similar encouraging results were obtained in another trial in 
HER2-negative breast cancer patients who fasted 24 h before and 
another 24 h after receiving chemotherapy (4). Although these 
were small pilot studies, initial results are promising.
Fasting is known to extend the life span of various organisms 
by acting on the same evolutionarily conserved nutrient-sensing 
pathways (5, 6). It is currently believed that the same pathways are 
involved in mediating the differential stress response to fasting 
between normal and cancerous cells. The underlying rationale is 
that, during the time of nutrient deprivation, an organism would 
flux resources away from growth and development and invest 
in maintenance and protective mechanisms. Consequently, a 
decrease in growth factors, such as IGF-I (1, 7), causes normal 
cells to downregulate proliferation and upregulate cell protective 
mechanisms. Thus, fasting induces the same protective mecha-
nisms against a number of adverse effects of chemotherapeutic 
agents. However, recent findings now also implicate additional 
mechanisms. In this article, we review emerging evidence sup-
porting a key role played by macroautophagy (hereafter referred 
to as autophagy) in not only attenuating the toxic effects of 
chemotherapy but also in enhancing the efficacy of antineoplas-
tic therapies. In particular, we highlight the ability of fasting to 
enhance immune surveillance, suggesting that short-term fast-
ing may provide best results in the context of chemotherapeutic 
agents that induce immunogenic cell death (ICD).
FASTinG-inDUCeD AUTOPHAGY: 
enHAnCinG CeLL SURvivAL
Autophagy is an evolutionarily conserved system by which cells 
degrade long-lived cellular components. During bouts of fasting, 
autophagy is upregulated in order to “digest” non-critical cellular 
components into substrate to be used for energy production as 
well as synthesis and repair of critical housekeeping proteins. 
However, autophagy is also upregulated in response to various 
stressors (8). For example, autophagy promotes cell survival in 
response to heavy metals (9) and hypoxia (10) and is also protec-
tive in systemic insults, such as sepsis (11).
Similarly, an upregulation of autophagy prior to the induc-
tion of a toxic chemotherapeutic agent may be protective. As an 
example, chemotherapy directly, or via an increase in oxidative 
stress, causes damage to organelles, such as the mitochondria 
(12). Here, autophagy plays a critical role in quality control of 
mitochondrial networks, targeting defective mitochondria for 
degradation (13). Similarly, in a sterile-injury model (third-
degree burn wounds in rabbits), mortality is dramatically 
increased when autophagy is inhibited (14). In particular, the 
accumulation of mitochondria with low membrane potential has 
been implicated as the causative agent in the pathology induced 
by autophagic insufficiency. Another key function of autophagy 
is to provide an alternative route for removing misfolded proteins 
when the proteasomal pathway is saturated. Indeed, endoplasmic 
reticulum (ER) stress, caused by an accumulation of misfolded 
proteins, also activates autophagy (15). Taken together, these 
observations suggest that a systemic upregulation of autophagy 
before chemotherapy is administered could be beneficial. Since 
fasting is a well-established mechanism for inducing autophagy, 
it seems likely that fasting-induced autophagy may play a critical 
role in limiting chemo-toxicity.
Fasting-induced upregulation of the autophagic process may 
render cells prepared to deal with a systemic challenge faced 
during chemotherapeutic induction. But importantly, this also 
raises the question whether fasting-induced autophagy may not 
similarly be protective to cancer cells. Indeed, the observation 
that inhibition of autophagy sensitizes cancer cells to therapeutic 
interventions demonstrates that autophagy also has a key pro-
survival function in numerous cancers (16–18). However, cancer 
cells often demonstrate a comparatively lower capacity to induce 
autophagy, since the development of cancer is often associated 
with a defect in autophagic capacity. As an example, oncogenes 
that are often upregulated in cancer (e.g., Akt, PI3K, and Bcl-2 
proteins) inhibit autophagy, whereas tumor suppressor genes often 
mutated or lost (e.g., DAPK1 and PTEN) are usually involved in 
the upregulation of autophagy (16, 17). This would suggest that, at 
least in some cancers, the differential stress response may in fact 
manifest from the inability of cancer cells to sustain autophagic 
processes as effectively as normal cells. Also, many growth factors 
potently inhibit autophagy by promoting the utilization of exog-
enous nutrients (19). The decrease in circulating growth factors 
may thus result in an upregulation of autophagy in normal cells, 
but not cancer cells that have developed insensitivity to external 
growth cues. Thus, there is reason to suspect that host cells, which 
are more responsive to fasting cues, may upregulate autophagy to 
a greater extent than cancer cells.
AUTOPHAGY AnD iMMUnOLOGiCAL 
CeLL DeATH
Accumulating evidence indicates that the antineoplastic effect of 
various chemotherapeutic agents is not only dependent on their 
cytotoxic effects but also that such agents exert their therapeutic 
effect through their ability to reinstate immune surveillance 
after inducing ICD in cancer cells (20). Mechanistically, certain 
chemotherapeutics (e.g., mitoxantrone and anthracyclines such 
as doxorubicin) that induce ER stress enhance the expression 
of calreticulin on the cell membrane, which in turn promotes 
the engulfment of apoptotic bodies by antigen-presenting cells 
(21). Another hallmark of ICD is the release of danger-associated 
molecules (DAPMPs), such as ATP, various heat shock proteins, 
and signaling molecules (e.g., cytokines such as IL-1α) (22). In 
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turn, the pro-inflammatory state induced by these DAMPs and 
inflammatory mediators promotes the maturation of dendritic 
cells and subsequent activation of CD4+ and CD8+ T-cells (22).
Interestingly, autophagy has also been shown to enhance the 
immunogenicity of dying tumor cells by secretion HMGB1 (23). 
Similarly, autophagy has been shown to play a critical role in 
mediating ICD through the release of ATP prior to apoptosis (24). 
This suggests that the recruitment of the autophagic machinery 
(e.g., by fasting) prior to administering chemotherapeutic agents 
known to induce ICD may enhance the therapeutic efficacy 
of these agents. Strikingly, recent findings show that this may 
indeed be the case. Fasting (48  h) or administering agents 
known to upregulate autophagy (hydroxycitrate) augments the 
antineoplastic properties of mitoxantrone and oxaliplatin, an 
effect which was not observed if cancer cells were implanted in 
immune-compromised mice, or if the critical autophagic gene 
Atg5 was silenced (25). In particular, the role of autophagy-
mediated ATP release is demonstrated by two observations. 
First, in autophagy-deficient cells, ATP release is attenuated. 
Second, cancer cells overexpressing CD39, an ecto-ATPase that 
rapidly converts ATP to AMP, demonstrated a marked decrease 
in chemotherapeutic efficacy, which was reversed by intra-tumor 
administration of ATPase inhibitors. The observation that fasting-
induced autophagy promotes ICD suggests novel mechanisms 
through which fasting may enhance chemotherapeutic efficacy. 
Since autophagy is involved in the secretion of other ICD agents 
(26), future studies may investigate whether fasting may similarly 
“prime” cells for autophagy-mediated release of ICD elicitors.
Furthermore, autophagy also plays a critical role in epitope 
expression. The prototypical view where MHC II epitopes are 
derived from exogenous (i.e., phagocytosed) sources and MHC 
I from endogenous sources has been supplemented by find-
ings indicating that phagocytosed particles could be expressed 
on MHC I (27), and conversely, that endogenous epitopes can 
be expressed by MHC II (28). While autophagy has a more 
established role in the expression of epitopes by MHC II (29), 
recent evidence has implicated autophagy in the expression of 
epitopes by MHC I (30). Macroautophagy provides a constant 
source of cytosolic proteins that fuse with MHC II loading 
compartments (29), suggesting that fasting-induced autophagy 
may increase the presentation of cytosolic epitopes. Supporting 
this view, autophagy, induced in vitro by starvation, enhances the 
expression of intracellular proteins on MHC II (31). Short-term 
fasting has also been shown to enhance the mucosal-derived B 
lymphocyte response to an orally administered influenza vaccine 
(32). Similarly, administration of the mTOR-inhibitor rapamycin 
enhances vaccine efficacy by promoting cross-strain protection 
(33). Similar to the effects of autophagy induction in enhancing 
vaccine efficacy, upregulating autophagy prior to chemotherapy 
may enhance immunization against tumor antigens.
In fact, there is evidence that autophagy may play an impor-
tant role in epitope presentation within an oncological context. 
As an example, autophagy, induced by either starvation or 
pharmacologically in antigen-donating cancer cells, enhances 
the cross-presentation of these antigens by dendritic cells (34). 
Also, recent findings suggest that a fusion construct consist-
ing of a cancer antigen (NY-ESO-1) with proteins targeting 
the cancer antigen for autophagic degradation could assist in 
epitope expression by MHC II and enhancement of CD4+ 
T cell-mediated antitumor responses (35). These observations 
suggest that the role of autophagy in managing various infec-
tions and promoting vaccine efficacy are likely also important 
in reinstating anticancer immune response. This then also sug-
gests that fasting may mediate therapeutic effects by enhancing 
epitope expression resulting from an upregulation of autophagic 
processes.
Initial findings from preclinical studies suggests that fasting 
my sensitize cancer cells to chemotherapeutic interventions (2). 
From the preceding discussion, it appears that an upregulation 
of autophagy may mediate such a “chemo-sensitizing” response 
by enhancing epitope presentation and augmenting the rein-
statement of immune surveillance. However, autophagy may 
also attenuate an inflammatory response and contribute toward 
cancer cells’ ability to evade immune effectors. As an example, 
though autophagy has been implicated in the unconventional 
secretion of IL-1β (36), a well-known pro-inflammatory cytokine, 
autophagy may also inhibit the expression of IL-1β production 
by targeting the activated inflammasome for autophagic degra-
dation (37). In addition, autophagy may also promote immune 
evasion by cancer cells. As an example, inhibition of autophagy 
in HRAS-transformed mouse kidney endothelium results in 
an altered proteome with a more pro-inflammatory profile, 
“priming” cells for an innate immune response (38). Similarly, 
inhibition of autophagy has also been shown to promote ICD in 
at least some tumors (39). Autophagy has also been implicated 
as a mechanism by which cancer cells avoid NK-mediated lysis 
by targeting granzyme B released for autophagic degradation 
(40). These observations demonstrate that autophagy may also 
play a role in mediating immune evasion by transformed cells.
OnCOLYTiC viRUSeS
Recently, evidence has emerged that fasting may also enhance 
the efficacy of oncolytic viruses (OVs) (41). In normal cells, 
fasting increases the phosphorylation status of translation initia-
tion factor eIF2α, resulting in a depression of protein synthesis; 
in contrast, cancer cells do not exhibit the same level of eIF2α 
phosphorylation. Consequently, viral growth is inhibited in 
fasting-responsive normal cells as they downregulate the transla-
tional machinery required for viral replication, while cancer cells 
remain insensitive (41). This may explain the sensitivity of cancer 
cells to the herpes simplex virus (HSV) compared to host cells 
when administered in a fasted state (41). It is likely that fasting 
may also induce similar results in other OVs. Since viruses are 
dependent on host replication machinery, fasting would suppress 
viral replication by downregulating cellular replication and trans-
lational activities. In contrast, cancer cells that are less responsive 
to fasting cues would maintain higher metabolic activity and thus 
be more susceptible to viral infections.
However, fasting-induced autophagy may also have an 
impact on oncolytic viral efficacy, since autophagy is also 
implicated in the host’s immune response toward viral infec-
tions (26, 42). As an example, upregulating autophagy by means 
of fasting results in a dramatic suppression of viral infections 
FiGURe 1 | Autophagy may remove cellular components damaged by antineoplastic therapies and also promote the reinstatement of immune 
surveillance against cancer cells.  
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(A) Autophagy plays a key role in the clearance of damaged cellular components and organelles. Removal of protein aggregates or damaged mitochondria may 
promote cell survival. (B) Autophagy is also involved in epitope expression. Exogenous antigens derived from cell bodies or secreted by cancer cells can be 
processed into epitopes to be loaded in MHC I and II loading compartments. Similarly, endogenous epitopes processed by autophagy can be expressed by cancer 
cells, enhancing their immunogenic profile. (C) Fasting may also have an impact on the efficacy of oncolytic viral therapy. Many viruses target diverse steps within 
the autophagic process for either viral subversion or inhibition of host antiviral response [reviewed by Chiramel et al. (42)]. Thus, autophagy may either promote or 
impede viral infectivity. Not illustrated, autophagy has also been implicated in the release of inflammatory mediators, such as IL-1β, ATP, and HMGB1, via secretory 
autophagy (26).
FiGURe 1 | Continued
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in a variety of cell types (43). This would suggest that fasting 
may preferentially sensitize autophagy-deficient cancer cells to 
HSV, as normal cells would be more resistant by virtue of the 
elevated levels of autophagy in cells responding to a fasted state. 
Of note, an upregulation of autophagy may not be beneficial 
to all types of viruses since certain viral agents also subvert 
autophagic processes for replication and the non-lytic release 
of viral particles (44). As an example, the hepatitis C virus 
is known to upregulate autophagy in hepatocytes, where the 
inhibition of autophagy in fact hampers viral replication as cells 
induce apoptotic cell death (45). Indeed, the key role played by 
autophagy in cell-autonomous defense against viral infections 
has also generated interest as pathways that may be targeted 
for enhancing OV efficacy (46). An upregulation of autophagy 
through fasting may thus either increase or decrease viral 
infectivity, since autophagy has different roles in the replication 
strategies of OVs.
Furthermore, viral subversion of autophagic processes is 
known to depend on the tissue type being infected (44). This 
would suggest that the tissue of origin in cancer may also have 
an impact on the outcome of fasting-induced autophagy in OV 
therapy. Intriguingly, recent evidence suggests that the evolution 
of drug resistance may also alter the role of autophagy in viral 
replication (47). Mice inoculated with A549 cancer cells that 
were either resistant to cisplatin (A549/DDP) or paclitaxel (A549/
PTX) demonstrated contrasting tumor growth rates in response 
to autophagy modulation: whereas the autophagy inhibitor 
chloroquine enhanced viral-induced cell death of A549/DDP 
cancer cells, the inhibition of autophagy by rapamycin rendered 
A549/PTX cells more susceptible to viral lysis. Thus, both tissue 
origin and the development of drug resistance are likely to have 
an impact on clinical trials where the role of fasting in OV therapy 
is evaluated.
Autophagy as a catabolic process plays a key immunologi-
cal role in enhancing cell-autonomous defenses, and, as such, 
pathogens such as viruses have evolved various strategies both 
to inhibit and to subvert this process (44, 48). Consequently, it is 
likely that upregulation of autophagy may not be effective for all 
OVs or even counterproductive. However, the role of autophagy 
in modulating viral infectivity also suggests that the genetic 
manipulation of OVs to render them more “autophagy-sensitive” 
might be an attractive strategy for treating autophagy-deficient 
cancers.
Therefore, it appears that fasting may have an impact on both 
viral and chemotherapeutic interventions via diverse mechanisms 
involving both an upregulation of autophagy and a decrease in 
circulating growth factors (Figure 1).
UnReSOLveD iSSUeS
Observations in mice suggest that fasting may represent a cost-
effective intervention that may greatly increase the therapeutic 
window. However, it is not obvious how fasting protocols for mice 
would translate to humans. Mice have a large surface-to-body 
ratio with a metabolic rate vastly higher than that of humans (49); 
therefore, the effect of 48 h of fasting in mice would have far more 
pronounced effects in a rodent model compared to humans. As 
an example, the rate of hepatic gluconeogenesis in mice is about 
11.4 times higher than in humans (49), suggesting that even 
48-h fasting for mice may in fact greatly upregulate catabolic 
processes in order to maintain glucose levels. This pronounced 
effect of fasting in mice is demonstrated by the observation that 
72  h of fasting induces a ~20% reduction in body weight (7). 
This raises the question whether more extreme fasting protocols 
need to be implemented in patients to replicate more accurately 
the metabolic consequences seen in mice. Prolonged fasting 
protocols that are necessary to induce a similar catabolic state 
in humans may not be feasible in many cancer patients who are 
already undernourished and lack the reserve capacity to tolerate 
prolonged bouts of fasting. These considerations thus highlight 
the need to understand the mechanisms by which fasting may 
benefit patients. As an example, the involvement of autophagy 
as a key mediator behind the effect of fasting would predict that 
prolonged fasting may not be necessary, as autophagy is rapidly 
upregulated even after short-term fasting (50). Also, the phar-
macological activation of key pathways involved in the fasting 
response is an attractive alternative to direct fasting.
Additional studies are needed to identify the context in which 
fasting may be beneficial. As mentioned, there are contrasting 
findings on the role of autophagy in ICD. Furthermore, it has been 
suggested that other interventions, such as radiotherapy, may also 
benefit from fasting regimes (51). In this regard, radiotherapy 
has also been shown to induce ICD in a number of tumors (52). 
Since autophagy can either inhibit or promote ICD, it is likely 
that fasting-induced autophagy may also alter the therapeutic 
outcome of radio therapy.
Fasting may also invoke mechanisms beyond modulating 
nutrient and growth factor levels. As an example, postprandial 
reabsorption of bile acids acts as singling molecules that could alter 
the effects of chemotherapy. Bile acids alter a range of immune and 
metabolic activities via farnesoid X receptor (FXR) (53). Even in 
a fasted state, the pharmacological activation of FXR suppresses 
autophagy by attenuating the transcription of autophagic genes 
(54). In addition, FXR also has an anti-inflammatory function 
(55). As an example, FXR activation leads to the downregulation 
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of monocyte chemoattractant protein-1 in macrophages (56). It 
remains to be established whether FXR signaling also modulates 
other peripheral immune effects. However, this does demonstrate 
that bile released in response to feeding may inhibit autophagy 
and also cause anti-inflammatory activity that may antagonize 
the mobilization of a robust immune response to cancer cells.
COnCLUSiOn
In this article, we have highlighted the potential protective role of 
fasting-induced autophagy as a mechanism by which cells cope 
with the adverse effects of chemotherapy. In addition, we have 
pointed out that since autophagy is also involved in immune 
responses it is possible that an upregulation of autophagy may 
have an impact on immune function and, in particular, help or 
hinder the reinstatement of immune surveillance against trans-
formed cells. Furthermore, fasting results in a range of physi-
ological adaptations which may have an impact on the efficacy of 
chemotherapeutic agents. It is likely that the protective effects of 
fasting may be mediated by these processes operating in concert. 
A clear understanding of the mechanism invoked by fasting may 
lead to the development of pharmacological strategies that rep-
licate these same processes. Such therapies may be of particular 
importance in patients who are already undernourished or where 
nutrient deprivation is contraindicated.
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